This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease
Daiello, Lori A.,
Ott, Brian R.,
Festa, Elena K.,
Friedman, Michael,
Miller, Lindsay A.,
Heindel, William C.
Objective: We conducted a combined observational cohort and case-control study in patients with Alzheimer disease (AD) to assess the effects of acetylcholinesterase inhibitor (ChEI) treatment on cognitive functions important for driving.; Methods: Performance of 24 outpatients with newly diagnosed (untreated) early-stage AD was compared before beginning ChEI (pre-ChEI) and after 3 months of therapy (post-ChEI) […]
Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design
Pelton, Gregory H.,
Andrews, Howard,
Roose, Steven P.,
Marcus, Sue M.,
D'Antonio, Kristina,
Husn, Hala,
Petrella, Jeffrey R.,
Zannas, Anthony S.,
Doraiswamy, P. Murali,
Devanand, D. P.
Treatment strategies for patients with depression and cognitive impairment (DEP-CI), who are at high risk to develop a clinical diagnosis of dementia, are not established. This issue is addressed in the donepezil treatment of cognitive impairment and depression (DOTCODE) pilot clinical trial. The DOTCODE study is the first long-term treatment trial that assesses differences in […]
Concentration of donepezil to the cognitive response in Alzheimer disease
Yang, Yuan-Han,
Chen, Chun-Hung,
Chou, Mei-Chuan,
Li, Chien-Hsun,
Liu, Ching-Kuan,
Chen, Su-Hwei
Background: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration.; Methods: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains […]
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial
Williamson, Jeff D.,
Launer, Lenore J.,
Bryan, R. Nick,
Coker, Laura H.,
Lazar, Ronald M.,
Gerstein, Hertzel C.,
Murray, Anne M.,
Sullivan, Mark D.,
Horowitz, Karen R.,
Ding, Jingzhong,
Marcovina, Santica,
Lovato, Laura,
Lovato, James,
Margolis, Karen L.,
Davatzikos, Christos,
Barzilay, Joshua,
Ginsberg, Henry N.,
Linz, Peter E.,
Miller, Michael E.
Importance: Persons with type 2 diabetes mellitus (T2DM) are at increased risk for decline in cognitive function, reduced brain volume, and increased white matter lesions in the brain. Poor control of blood pressure (BP) and lipid levels are risk factors for T2DM-related cognitive decline, but the effect of intensive treatment on brain function and structure […]
The long-term efficacy and tolerability of donepezil in patients with vascular dementia
Wilkinson, David,
Róman, Gustavo,
Salloway, Stephen,
Hecker, Jane,
Boundy, Karyn,
Kumar, Dinesh,
Posner, Holly,
Schindler, Rachel
Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD).; Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer’s […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]